全文获取类型
收费全文 | 2472篇 |
免费 | 145篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 17篇 |
儿科学 | 62篇 |
妇产科学 | 45篇 |
基础医学 | 361篇 |
口腔科学 | 44篇 |
临床医学 | 229篇 |
内科学 | 456篇 |
皮肤病学 | 29篇 |
神经病学 | 251篇 |
特种医学 | 109篇 |
外国民族医学 | 2篇 |
外科学 | 466篇 |
综合类 | 36篇 |
一般理论 | 5篇 |
预防医学 | 152篇 |
眼科学 | 57篇 |
药学 | 160篇 |
中国医学 | 14篇 |
肿瘤学 | 133篇 |
出版年
2023年 | 29篇 |
2022年 | 65篇 |
2021年 | 158篇 |
2020年 | 76篇 |
2019年 | 120篇 |
2018年 | 98篇 |
2017年 | 97篇 |
2016年 | 90篇 |
2015年 | 72篇 |
2014年 | 128篇 |
2013年 | 142篇 |
2012年 | 183篇 |
2011年 | 168篇 |
2010年 | 103篇 |
2009年 | 66篇 |
2008年 | 129篇 |
2007年 | 120篇 |
2006年 | 105篇 |
2005年 | 107篇 |
2004年 | 83篇 |
2003年 | 68篇 |
2002年 | 48篇 |
2001年 | 31篇 |
2000年 | 39篇 |
1999年 | 45篇 |
1998年 | 10篇 |
1997年 | 7篇 |
1996年 | 15篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 6篇 |
1992年 | 17篇 |
1991年 | 17篇 |
1990年 | 7篇 |
1989年 | 10篇 |
1988年 | 8篇 |
1987年 | 8篇 |
1986年 | 9篇 |
1985年 | 13篇 |
1984年 | 7篇 |
1983年 | 9篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1975年 | 5篇 |
1974年 | 13篇 |
1973年 | 9篇 |
1972年 | 8篇 |
1971年 | 9篇 |
1970年 | 5篇 |
1966年 | 5篇 |
排序方式: 共有2628条查询结果,搜索用时 0 毫秒
41.
42.
Despite their indisputable clinical value, current tissue engineering strategies face major challenges in recapitulating the natural nano-structural and morphological features of native bone. The aim of this study is to take a step forward by developing a porous scaffold with appropriate mechanical strength and controllable surface roughness for bone repair. This was accomplished by homogenous dispersion of carbon nanotubes (CNTs) in a poly(lactide-co-glycolide) (PLGA) solution followed by a solvent casting/particulate leaching scaffold fabrication. Our results demonstrated that CNT/PLGA composite scaffolds possessed a significantly higher mechanical strength as compared to PLGA scaffolds. The incorporation of CNTs led to an enhanced surface roughness and resulted in an increase in the attachment and proliferation of MC3T3-E1 osteoblasts. Most interestingly, the in vitro osteogenesis studies demonstrated a significantly higher rate of differentiation on CNT/PLGA scaffolds compared to the control PLGA group. These results all together demonstrate the potential of CNT/PLGA scaffolds for bone tissue engineering as they possess the combined effects of mechanical strength and osteogenicity. 相似文献
43.
Isabel Siow Keng Siang Lee John J.Y. Zhang Seyed Ehsan Saffari Adeline Ng Barnaby Young 《Journal of stroke and cerebrovascular diseases》2021,30(3):105549
IntroductionCOVID-19 is a multi-system infection which predominantly affects the respiratory system, but also causes systemic inflammation, endothelialitis and thrombosis. The consequences of this include renal dysfunction, hepatitis and stroke. In this systematic review, we aimed to evaluate the epidemiology, clinical course, and outcomes of patients who suffer from stroke as a complication of COVID-19.MethodsWe conducted a systematic review of all studies published between November 1, 2019 and July 8, 2020 which reported on patients who suffered from stroke as a complication of COVID-19.Results326 studies were screened, and 30 studies reporting findings from 55,176 patients including 899 with stroke were included. The average age of patients who suffered from stroke as a complication of COVID-19 was 65.5 (Range: 40.4–76.4 years). The average incidence of stroke as a complication of COVID-19 was 1.74% (95% CI: 1.09% to 2.51%). The average mortality of stroke in COVID-19 patients was 31.76% (95% CI: 17.77% to 47.31%). These patients also had deranged clinical parameters including deranged coagulation profiles, liver function tests, and full blood counts.ConclusionAlthough stroke is an uncommon complication of COVID-19, when present, it often results in significant morbidity and mortality. In COVID-19 patients, stroke was associated with older age, comorbidities, and severe illness. 相似文献
44.
Shirvani Hossein Rostamkhani Fatemeh Arabzadeh Ehsan Mohammadi Faezeh Mohammadi Fatemeh 《Sport Sciences for Health》2021,17(4):849-854
Sport Sciences for Health - The widespread prevalence and mortality of coronavirus diseases-2019 (COVID-19) lead many researchers to study the SARS-CoV-s2 infection to find a treatment for this... 相似文献
45.
46.
Xu Zheyu Anderson Kirstie N. Saffari Seyed Ehsan Lawson Rachael A. Chaudhuri K. Ray Brooks David Pavese Nicola 《Journal of neurology》2021,268(1):312-320
Journal of Neurology - Sleep disorders can occur in early Parkinson’s disease (PD). However, the relationship between different sleep disturbances and their longitudinal evolution has not... 相似文献
47.
Shirazi Mohsen Ahmad Akhoundi Mohammad Sadegh Javadi Ehsan Kamali Abbas Motahhari Pouria Rashidpour Mahsa Chiniforush Nasim 《Lasers in medical science》2015,30(2):713-718
Lasers in Medical Science - Low-level laser has been indicated to have the capability to facilitate the differentiation of the osteoclastic and osteoblastic cells which are responsible for the bone... 相似文献
48.
Ventricular Assist Devices and Increased Blood Product Utilization for Cardiac Transplantation 下载免费PDF全文
49.
Olle Muren Ehsan Akbarian Mats Salemyr Henrik Bodén Thomas Eisler André Stark Olof Sk?ldenberg 《Acta orthopaedica》2015,86(5):569-574
Background and purpose
We have previously shown that during the first 2 years after total hip arthroplasty (THA), periprosthetic bone resorption can be prevented by 6 months of risedronate therapy. This follow-up study investigated this effect at 4 years.Patients and methods
A single-center, double-blind, randomized placebo-controlled trial was carried out from 2006 to 2010 in 73 patients with osteoarthritis of the hip who were scheduled to undergo THA. The patients were randomly assigned to receive either 35 mg risedronate or placebo orally, once a week, for 6 months postoperatively. The primary outcome was the percentage change in bone mineral density (BMD) in Gruen zones 1 and 7 in the proximal part of the femur at follow-up. Secondary outcomes included migration of the femoral stem and clinical outcome scores.Results
61 of the 73 patients participated in this 4-year (3.9- to 4.1-year) follow-up study. BMD was similar in the risedronate group (n = 30) and the placebo group (n = 31). The mean difference was −1.8% in zone 1 and 0.5% in zone 7. Migration of the femoral stem, the clinical outcome, and the frequency of adverse events were similar in the 2 groups.Interpretation
Although risedronate prevents periprosthetic bone loss postoperatively, a decrease in periprosthetic BMD accelerates when therapy is discontinued, and no effect is seen at 4 years. We do not recommend the use of risedronate following THA for osteoarthritis of the hip.Adaptive bone remodeling around the femoral stem following total hip arthroplasty (THA) results in regional loss of bone mass, especially in proximal parts of the femur—most of which takes place within the first postoperative year (Bodén et al. 2006, Sköldenberg et al. 2006). Periprosthetic bone loss may predispose to periprosthetic fracture, aseptic loosening, and difficulties at revision surgery (Lindahl 2007, Streit et al. 2011, Sköldenberg et al. 2014).The bisphosphonate (BP) risedronate has been used successfully to prevent osteoporotic fractures, mainly in the hip and vertebrae, by inhibiting osteoclast activity (McClung et al. 2001). In recent years, the possible use of BPs to prevent or ameliorate periprosthetic adaptive bone resorption, osteolysis, and implant migration has been investigated thoroughly in animal models and humans. The short-term results of several studies showing the effects of postoperative BP treatment in reducing periprosthetic bone loss up to a year after the arthroplasty have already been published (Venesmaa et al. 2001, Wilkinson et al. 2001, Hennigs et al. 2002, Wilkinson et al. 2005, Arabmotlagh et al. 2006).We have previously found that risedronate given once a week for 6 months after THA reduces periprosthetic bone resorption around an uncemented femoral stem in the first and second postoperative year (Sköldenberg et al. 2011). We now report the 4-year outcome in the same cohort. 相似文献50.
During recent years, molecular techniques have significantly impacted our understanding and therapeutic concepts in gastrointestinal and liver disease. In a number of diseases, diagnostic work-up includes molecular data that supplements the phenotypical evaluation. This includes monogenic diseases as well as the identification of genetic risk factors (e. g. NOD2/CARD15 mutation in Crohn's disease) and viral disease. Attempts to replace liver transplantation in hereditary liver disease by targeted molecular interventions (e. g. via viral vectors) are still experimental, but the associated techniques have improved considerably. The molecular identification of therapeutic targets was followed by the development of specifically tailored therapeutics. These agents are mainly used in the treatment of chronic inflammatory bowel disease and gastrointestinal tumors. 相似文献